The PennZone

  • Home
  • Business
  • Health
  • Non-profit
  • Education
  • Technology
  • Entertainment
  • Financial
  • Marketing

Blackrock Neurotech and University of Pittsburgh to Expand Reach of Brain-Computer Interface Trials with In-Home System
The PennZone/10187978

Trending...
  • CCHR Florida: Mental Health Awareness Month Open House
  • xREnergy up as much as +3,094,634% on first day listed on the XRP Ledger. Ticker : $XRE
  • Bonelli Systems Expands Managed IT Services Nationwide, Leveraging Microsoft Azure Expertise
A compact, remote BCI system will enable expansion of in-home study sessions, extending the geographic reach and number of individuals that can participate in BCI research.

SALT LAKE CITY, June 21, 2022 /PRNewswire/ -- Brain-computer interface (BCI) trials may soon be more accessible to a greater population of candidates living with paralysis, per a new partnership agreement between Blackrock Neurotech, a leader in implantable brain technology, and the University of Pittsburgh's Rehab Neural Engineering Labs (Pitt RNEL). The agreement sets the stage for Pitt RNEL to scale future brain-computer interface (BCI) studies, enabling more people with remote BCI systems to participate in study sessions from their homes. Pitt RNEL is also creating a process to expand and improve participant recruitment, both remote and on-site, ultimately enabling larger studies with greater numbers of volunteers.

Since 2004, implantable BCIs have offered people with spinal cord injuries and other neurological disorders the potential to restore abilities. These BCI systems, comprised of miniaturized electronics, hardware, and machine learning software, decode and translate brain signals into digital commands, providing people with paralysis the ability to control external devices such as computer cursors or robotic arms.

Pitt was among the first research centers to implant Blackrock's BCI in human participants and has since conducted pioneering trials on a range of BCI applications, including complex control of robotic limbs and restoring sensory feedback using electrical stimulation of the brain. However, participation in Pitt's clinical trials has, up to now, largely been limited to people living within driving distance of the institution.

"Typical experiments require participants to come into our lab facilities on a regular basis, which is a successful model that will continue to be essential in pushing BCI science forward for years to come," said Michael Boninger, professor of physical medicine and rehabilitation and investigator in the Rehab Neural Engineering Labs at Pitt. "However, home testing has become an important supplement to lab testing whereby we enlist study staff to attend sessions and transport parts of the lab equipment to the participant's home to conduct testing. With this new initiative, we will develop a miniaturized and streamlined BCI system designed to work in people's homes, while replicating the potential for complex lab-based experiments."

More on The PennZone
  • Fairmint Introduces First Fully Onchain and Open Cap Table Infrastructure
  • Vortex Brands Begins Gold Purchases Under New Joint Venture with Dubai-Based Partner
  • Author Chandra Donelson Visits the Children's Museum of Pittsburgh
  • Chandra Donelson Headlines the Hike2 Innovation Summit 2025
  • NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3

Under this newly funded collaboration, BCI sessions using this new system will occur at the homes of people participating in the study, demonstrating that BCI research can extend outside of the greater Pittsburgh area. By reducing the challenge of study-related travel, researchers can test a broader population of participants and collect more diverse safety and efficacy data. Importantly, these in-home BCI trials are distinct from other at-home trials Pitt has conducted, where portable systems have been used independently by participants for limited testing and recreational purposes.

The Pitt RNEL group has previously shown that a portable BCI system could be successfully used at home to perform a variety of tasks by imagining the movement of a mouse cursor on the system's integrated monitor, ranging from playing computer games and typing sentences to creating digital art.

"I first started using the portable system on my own in the summer of 2020, when COVID shut down testing at the lab," said study participant Nathan Copeland. "I think in-home devices are the next essential step for getting BCI technology into the brains of the people that could have their lives improved by it. Whether it's to draw cute cats, play video games, or as a primary tool for communication, the capability of using the system in the real world beyond the confines of a lab building will start changing lives and how people think about BCI."

The expanded trials and compact system are an important step in Blackrock's efforts to make the first BCI platform commercially available to people with paralysis. The technology, which has been chronically implanted in humans since 2004, has until now only been available to patients through research studies – but Blackrock believes it is ready for real-world use.

"At a neuroscience conference a few years ago, three participants in clinical trials of Blackrock devices sat on a panel and expressed a consensus that our technology addressed immediate needs in their lives," said Marcus Gerhardt, CEO and co-founder of Blackrock. "Through this expansion of our partnership with Pitt, we will be able to connect with and learn from larger patient populations, with the guiding vision of making the technology available to as many patients as possible."

More on The PennZone
  • Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
  • Actuated Medical Launches Participating Preferred Series A Round, Led by Keiretsu Forum Mid-Atlantic, South-East, & Texas
  • ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
  • Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain
  • Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa

More information on the remote trials and recruitment efforts at the University of Pittsburgh can be found here.

About Blackrock Neurotech

Blackrock Neurotech is dedicated to the clinical translation of brain-computer interface (BCI) technology. Blackrock, founded in 2008, is the world's leading platform company for BCI technology and the development of implantable solutions that improve human lives. Blackrock's precision electrode technology is at the core of many worldwide innovations in BCI, enabling dozens of early users (known as "BCI Pioneers") to SeeAgain, HearAgain, MoveAgain and more. For more information, visit https://blackrockneurotech.com/

About the University of Pittsburgh Schools of the Health Sciences

The University of Pittsburgh Schools of the Health Sciences include the schools of Medicine, Nursing, Dental Medicine, Pharmacy, Health and Rehabilitation Sciences, and Public Health. The schools serve as the academic partner to UPMC. Together, their combined mission is to train tomorrow's health care specialists and biomedical scientists, engage in groundbreaking research that will advance understanding of the causes and treatments of disease, and participate in the delivery of outstanding patient care. Pitt has ranked among the top recipients of funding from the National Institutes of Health since 1998. For additional information about Pitt Health Sciences, please visit https://www.health.pitt.edu/.

Media contact:
Lightspeed PR/M for Blackrock
[email protected]

SOURCE Blackrock Neurotech
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • ABM for Good™ Launches First Project with Build Change
  • Braces for Teenagers in Allentown Offered by Exeter Smiles
  • Roots for Boots to Host "Bike Day Bash" Featuring Trike Presentation to Local Veteran
  • JOSHWAY Cuts Ribbon on New Brick-and-Mortar Location
  • ImagineX, in Collaboration with Qualys, Launches New mROC Services to Transform Enterprise Cyber Risk Management
  • Ditch Micromanagement: New Leadership Book for Results-Driven, Accountability-Based Teams
  • Jay Tapp was named Managing Director in British Columbia
  • Children's Hospital of Philadelphia Researchers Recommend New Standard of Care for Families with Hereditary Neuroblastoma Linked to ALK Mutation
  • GormanSquared Announces Provisional Patent
  • Hubei Heavy Equipment Makes a Striking Appearance at CIMT and Competes with International Brands
  • 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
  • NASDAQ Uplisting for Higher Market Exposure and Wide Corporate Benefits to AI Boosted Marketing Company On Track Towards $1 Billion Revenue by 2027
  • Congressional Men's Health Caucus Shows Bipartisan Consensus and Focus on Prevention, Mental Health, and Closing the Lifespan Gap
  • Chewy Chums™ Launches NeverBite™ on Kickstarter
  • DuoKey, Axiomtek and Blue Edge Network Partner to Enhance Smart Cities with Privacy-Preserving Urban Safeguarding and Fleet Management
  • Fangzhou Launches Otsuka's Third-Generation Leukemia Drug Ponatinib on its Platform
  • Viatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors
  • Austin Keen Joins WakeFX RopePal as Official Brand Ambassador
  • Bonelli Systems Expands Managed IT Services Nationwide, Leveraging Microsoft Azure Expertise
  • $4.3 Million Patent Application Waiver Fee Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression & PTSD: NRX Pharma

Popular on PennZone

  • Gas Wolf® Officially Becomes a Registered Trademark - 1267
  • Village Vapes and Cooking 4 Autism Announce Inaugural Partnership at MEGA 420 EVENT - 138
  • Jed the Fish, The Rapscallion of Los Angeles KROQ's Airwaves and Provocateur, Has Signed Off at 69 - 116
  • The World's No.1 Superstar Champions the NO FAKES Act – Secures Global Identity and Cultural Legacy
  • Goosechase Rolls Out Unlockable Missions, Its Most Anticipated Feature Yet
  • Portland Hosts Mensa's 2025 Mind Games®
  • PebblePad Welcomes Justin Reilly as New CEO to Drive Innovation and Growth
  • HR Tech Awards Program Celebrates 6th Year: Showcases Top Hiring, Talent, and HR Technologies
  • Museum Hack Presents Hacked Gala: A Rebellious Night of Art, Fashion, and Change at the Met
  • ServiceAgent.ai Brings 24/7 AI Call Answering to America's Home Services

Similar on PennZone

  • Asset-Backed Green Crypto: Fueling the Trillion-Dollar Revolution
  • QVC Honors Elton John with Inaugural Icon Award
  • NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
  • Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain
  • Cybersecurity is Protecting Your Personal Information and Your Portfolio
  • The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
  • $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
  • SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
  • Ditch Micromanagement: New Leadership Book for Results-Driven, Accountability-Based Teams
  • Jay Tapp was named Managing Director in British Columbia
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us